Kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD. Kobe2602 at 20 μM efficiently inhibited the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing H-Ras G12V. Moreover, Kobe2602 exhibits antitumor activity on a xenograft of human colon carcinoma SW480 cells carrying the K-ras(G12V) gene by oral administration.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: 10 mg/mL|
Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.
Shima F, et al. Enzymes. 2013;34 Pt. B:1-23. PMID: 25034098.
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
Shima F, et al. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. PMID: 23630290.
|Related Ras Products|
ARS-1630 is a novel mutant K-ras G12C inhibitor.
ARS-1323 is a novel inhibitor of mutant K-ras G12C.
ARS-1620 is an atropisomeric selective KRAS-G12C inhibitor with desirable pharmacokinetics.
ML-098 is an activator of the GTP-binding protein Rab7 with EC50 value of 77.6 nM.
CCG-1423 is a novel specific inhibitor of RhoA transcriptional signaling.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.